AMICA platform to integrate data from Radiohead immunotherapy study, enhancing drug discovery and reducing clinical trial risk

Immunai has announced a new collaboration with the Parker Institute for Cancer Immunotherapy (PICI) to create one of the largest single-cell datasets from a real-world cancer immunotherapy cohort, with the aim of accelerating drug discovery and de-risking clinical trials.

The partnership will see Immunai, a biotechnology company specializing in artificial intelligence-powered immune mapping, perform single-cell RNA sequencing (scRNA-seq) and multi-omic profiling on blood samples collected from over 1,000 patients enrolled in PICI’s Radiohead study. Radiohead (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) is a prospective longitudinal study tracking 1,070 individuals receiving immune checkpoint inhibitor treatments in real-world, community-based settings.

The resulting data will be integrated into Immunai’s proprietary AMICA (Annotated Multi-omic Immune Cell Atlas) platform, allowing researchers to compare immune responses across a broad spectrum of cancer types. These include non-small cell and small cell lung cancer, gastric cancer, hepatocellular carcinoma, melanoma, and others.

According to the companies, the dataset will become one of the most comprehensive single-cell multi-omic collections derived from a pan-cancer patient cohort treated with standard-of-care immunotherapies. It is expected to reveal new insights into the mechanisms of immune response and resistance that influence treatment outcomes.

To support this project, Immunai will use Chromium GEM-X technology from 10x Genomics, enabling high-throughput, single-cell analysis at unprecedented resolution.

“PICI was built to support bold science that brings real benefit to patients,” said Dr Tarak Mody, chief business officer at PICI. “Our mission to turn all cancers into curable diseases starts with understanding why treatments work for some people and not for others. Our collaboration with Immunai gives researchers a powerful resource to decode immune responses in real-world patients—and ultimately, to bring better immunotherapies to the people who need them most.”

Immunai’s CEO and co-founder, Dr Noam Solomon, said the collaboration demonstrates the potential of AI and multi-omic profiling to reshape oncology research.

“The Radiohead cohort allows us to publicly showcase the kind of single-cell multi-omic profiling we typically conduct privately with biopharma and biotechnology companies,” Solomon said. “This dataset offers a unique glimpse into the depth of insights our platform can provide, empowering scientists and drug developers to pinpoint which patients are most likely—or least likely—to benefit from new therapies.”

Both organizations believe the initiative will help overcome key hurdles in immuno-oncology by expanding the availability of high-resolution, real-world data that reflect clinical complexity beyond controlled trials.